A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

NCT06917872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-16

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.

Conditions

  • Healthy

Interventions

DRUG

BI 1291583

BI 1291583

DRUG

erythromycin

erythromycin

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-29
Primary Completion
2025-09-09
Completion
2025-09-09

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917872 on ClinicalTrials.gov